The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
GP Dr Roger Henderson provides an overview of the chronic complications of diabetes and the key preventive measures ...
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
In recent weeks, reports have been circulating about severe reactions in people who've taken over-the-counter vitamin B6 ...
Dr. Jeffrey K. Moore and West Clinical Research are proud to announce the grand opening of their new clinical research site, ...
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.
The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...
SLEEP is essential for good health and well-being. It keeps heart health in check, helps you maintain a healthy weight, makes ...